https://orcid.org/0000-0001-8081-0465
References
- Bron AJ, Tripathi RC. Cystic disorders of the corneal epithelium. I. Clinical aspects. Br J Ophthalmol 1973; 57: 361–375.
- Keay L, Jalbert I, Sweeney DF et al. Microcysts: clinical significance and differential diagnosis. Optom St Louis Mo 2001; 72: 452–460.
- Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet 2002; 41: 705–718. doi:10.2165/00003088-200241100-00002.
- Hopen G, Mondino BJ, Johnson BL et al. Corneal toxicity with systemic cytarabine. Am J Ophthalmol 1981; 91: 500–504. doi:10.1016/0002-9394(81)90240-3.
- Lass JH, Lazarus HM, Reed MD et al. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am J Ophthalmol 1982; 94: 617–621. doi:10.1016/0002-9394(82)90006-x.
- Özcan G, Özlenen Uçakhan Ö. Cytarabine-induced corneal toxicity: clinical features and relief of symptoms with loteprednol etabonate 0.5% in two patients. Turk J Ophthalmol 2021; 51: 114–117. doi:10.4274/tjo.galenos.2020.99248.
- Kumar L, Dua H, Agarwal S et al. Ocular toxicity of low dose cytosar. N Z Med J 1987; 100: 361.
- Lochhead J, Salmon JF, Bron AJ. Cytarabine-induced corneal toxicity. Eye 2003; 17: 677–678. doi:10.1038/sj.eye.6700451.
- Lazarus HM, Hartnett ME, Reed MD et al. Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol 1987; 104: 476–480. doi:10.1016/s0002-9394(14)74104-2.
- Herzig RH, Wolff SN, Lazarus HM et al. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361–369.